Pipeline

显示出强大临床性能和对患者有益的先进药物.

Pipeline
90
+
compounds, 单独或在合作或许可协议下开发的设备或适应症
investment
$7.8
b
R&D投资2023年
Commitment
50
+
项目正处于中期和后期开发阶段
Novel
80
%
在临床开发具有新的作用机制的化合物

Pipeline

2024年5月13日更新

Sort By 
Focus Area
分子/资产阶段
分子/资产类型
设备资产阶段
Device Asset Type
ABBV-151 (livmoniplimab) + abbv - 181 (budigalimab)
Biologic GARP-TGF-β1 Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Liver
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
非小细胞肺癌
N ∕ A
N ∕ A phase2
phase2
ABBV-319
Biologic ∕甾体ADC Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
Lutikizumab
Biologic Immunology Pharmaceutical IL-1a ∕ 1b
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
位患化脓性汗腺炎
N ∕ A
N ∕ A phase2
phase2
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
ABBV-706
SEZ6 + Topo-1 ADC Biologic Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
小细胞肺癌
N ∕ A
N ∕ A phase1
phase1
abbv - 181 (budigalimab)
Biologic Pharmaceutical anti-PD1 Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-CLS-579
Small Molecule Pharmaceutical Oncology PTPN2 ∕ N1
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-CLS-484
Small Molecule Pharmaceutical Oncology PTPN2 ∕ N1
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-514
Biologic Pharmaceutical Oncology N ∕ A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
IMGN-151
Biologic fr - α + DM21类麦黄素 Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ovarian Cancer
N ∕ A
N ∕ A phase1
phase1
Endometrial Cancer
N ∕ A
N ∕ A phase1
phase1
ABBV-969
Biologic PSMA ∕ STEAP1 ADC Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
mCRPC
N ∕ A
N ∕ A phase1
phase1
Pivekimab Sunirine (PVEK)
Biologic Pharmaceutical Oncology CD123 +吲哚啉苯二氮卓类dna靶向载荷
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
BPDCN
N ∕ A
N ∕ A phase2
phase2
急性髓性白血病
N ∕ A
N ∕ A phase2
phase2
ABBV-787
N ∕ A Pharmaceutical Oncology N ∕ A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
急性髓性白血病
N ∕ A
N ∕ A phase1
phase1
ABBV-303
∕多特异性抗体 c-Met Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-525
Small Molecule Pharmaceutical MALT1 Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
ABBV-453
Small Molecule Pharmaceutical Oncology Bcl-2
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
复发/难治性多发性骨髓瘤
N ∕ A
N ∕ A phase1
phase1
Imbruvica
BTK Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
滤泡淋巴瘤
US , EU
US , EU phase3
phase3
Venclexta™
Small Molecule Pharmaceutical Oncology Bcl-2
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
急性淋巴细胞白血病
N ∕ A
N ∕ A phase1
phase1
急性髓性白血病
US , EU
US , EU approved
approved
急性髓系白血病移植后
N ∕ A
N ∕ A phase3
phase3
慢性淋巴细胞白血病伴17p缺失
US , EU
US , EU approved
approved
一线慢性淋巴细胞白血病
US , EU
US , EU approved
approved
骨髓增生异常综合征
US , EU
US , EU phase3
phase3
复发性慢性淋巴细胞白血病
US , EU
US , EU approved
approved
Armour Thyroid
Large Molecule Pharmaceutical T3T4 Other Specialties
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hypothyroidism
N ∕ A
N ∕ A phase2
phase2
ABBV-951
Dopamine Receptor Small Molecule Pharmaceutical Neuroscience Combination
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
帕金森病
EU US
EU approved
US submitted
approved
submitted
BOTOX®
Large Molecule Pharmaceutical Neuroscience SNARE Proteins
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
发作性偏头痛预防
N ∕ A
N ∕ A phase3
phase3
Essential Tremor
N ∕ A
N ∕ A phase2
phase2
CLBR001 + SWI019
Biologic Pharmaceutical Oncology Partner Asset CD19
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
BOTOX®
Large Molecule Pharmaceutical SNARE Proteins Other Specialties
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
IC BPS
N ∕ A
N ∕ A phase2
phase2
SKYRIZI®
Biologic Immunology IL-23 Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
US , EU
US , EU approved
approved
Psoriasis
US , EU
US , EU approved
approved
银屑病关节炎
US , EU
US , EU approved
approved
Ulcerative Colitis
N ∕ A
N ∕ A submitted
submitted
阿唑南/阿维巴坦
Small Molecule Pharmaceutical PBP3 Other Specialties
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
复杂的革兰氏阴性感染
N ∕ A
N ∕ A phase3
phase3
ALPN-101
Biologic 双重CD28-ICOS拮抗剂 Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
系统性红斑狼疮(SLE)
Global
Global phase2
phase2
ABBV-552
Small Molecule Pharmaceutical Neuroscience SV2A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
阿尔茨海默病
N ∕ A
N ∕ A phase2
phase2
AL002
TREM 2 Biologic Pharmaceutical Neuroscience Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
阿尔茨海默病
N ∕ A
N ∕ A phase2
phase2
TTX-030
Biologic Pharmaceutical Oncology CD39 Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
晚期胰腺癌
N ∕ A
N ∕ A phase2
phase2
AGN-193408
Intracameral植入 Pharmaceutical Eye Care PGF2受体
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
开角型青光眼
N ∕ A
N ∕ A phase2
phase2
眼高血压
N ∕ A
N ∕ A phase2
phase2
ABBV-916
Biologic AßpE3 Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
阿尔茨海默病
N ∕ A
N ∕ A phase2
phase2
ABBV-668
Immunology RIPK1 Small Molecule Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
CUG-252
IL-2 Mutein Biologic Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
系统性红斑狼疮(SLE)
N ∕ A
N ∕ A phase1
phase1
CLF065
GLP-2 agonist Biologic Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
IBD
N ∕ A
N ∕ A phase1
phase1
ABBV-RGX-314
Biologic Pharmaceutical Eye Care Partner Asset VEGF
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
湿性黄斑变性(视网膜下)
N ∕ A
N ∕ A phase3
phase3
湿性黄斑变性(脉络膜上)
N ∕ A
N ∕ A phase2
phase2
糖尿病视网膜病变(脉络膜上病变)
N ∕ A
N ∕ A phase2
phase2
ABBV-CLS-7262
eIF2B Small Molecule Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
肌萎缩侧索硬化(ALS)
N ∕ A
N ∕ A phase2
phase2
消失性白质病(VWM)
N ∕ A
N ∕ A phase1
phase1
Telisotuzumab vedotin (ABBV-399)
Biologic c-Met Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
非小细胞肺癌
N ∕ A
N ∕ A phase3
phase3
ABBV-101
BTK Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
QULIPTA™
Small Molecule Pharmaceutical CGRP Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
慢性偏头痛预防
US , EU
US , EU approved
approved
发作性偏头痛预防
US , EU
US , EU approved
approved
BoNTE
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Glabellar Lines
N ∕ A
N ∕ A phase3
phase3
BOTOX®
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
阔肌突出
N ∕ A
N ∕ A submitted
submitted
咬肌突出
CN N ∕ A
CN submitted
N ∕ A phase3
submitted
phase3
OpSCF
Biologic Immunology Pharmaceutical Partner Asset SCF248
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Atopic Dermatitis
N ∕ A
N ∕ A phase2
phase2
Epcoritamab
Biologic DuoBody-CD3xCD20 Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
复发性∕难治性弥漫性大b细胞淋巴瘤
US , EU
US , EU approved
approved
复发性滤泡性淋巴瘤
N ∕ A
N ∕ A submitted
submitted
一线滤泡性淋巴瘤
N ∕ A
N ∕ A phase3
phase3
一线大b细胞淋巴瘤
US , EU
US , EU phase3
phase3
b细胞非霍奇金淋巴瘤
N ∕ A
N ∕ A phase2
phase2
复发性慢性淋巴细胞白血病
N ∕ A
N ∕ A phase1
phase1
Richter's Syndrome
N ∕ A
N ∕ A phase1
phase1
Elezanumab (abt - 555)
Biologic RGMa Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Spinal Cord Injury
N ∕ A
N ∕ A phase2
phase2
急性缺血性中风
N ∕ A
N ∕ A phase2
phase2
ABBV-932
Small Molecule Pharmaceutical DRD2∕DRD3调制器 Neuroscience Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Bipolar Depression
N ∕ A
N ∕ A phase1
phase1
RINVOQ™
Immunology Small Molecule JAK1 Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alopecia Areata
N ∕ A
N ∕ A phase3
phase3
强直性脊柱炎
US , EU
US , EU approved
approved
Atopic Dermatitis
US , EU
US , EU approved
approved
Axial SpA
US , EU
US , EU approved
approved
Crohn's Disease
US , EU
US , EU approved
approved
巨细胞动脉炎
US , EU
US , EU phase3
phase3
位患化脓性汗腺炎
N ∕ A
N ∕ A phase3
phase3
银屑病关节炎
US , EU
US , EU approved
approved
类风湿性关节炎
US , EU
US , EU approved
approved
系统性红斑狼疮(SLE)
N ∕ A
N ∕ A phase3
phase3
Takayasu指出动脉炎
JA
JA phase3
phase3
Ulcerative Colitis
US , EU
US , EU approved
approved
Vitiligo
N ∕ A
N ∕ A phase3
phase3
ABBV-400
Biologic cMET + Topo-1 ADC Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Colorectal Cancer
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-1882
抗pd1和抗a4b7单抗 Biologic Pharmaceutical Other Specialties
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
HIV
N ∕ A
N ∕ A phase2
phase2
Elahere
fr - α + DM4类麦黄素 Biologic Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
铂耐药卵巢癌
N ∕ A
N ∕ A approved
approved
铂敏感卵巢癌
N ∕ A
N ∕ A phase3
phase3
ABBV-383
CD3-BCMA Biologic Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
Status
Multiple Myeloma
N ∕ A
N ∕ A phase3
phase3
免疫球蛋白轻链淀粉样变
N ∕ A
N ∕ A phase1
phase1
Juvederm®voluma®xc
Facial Aesthetics Device Aesthetics Combination 年龄相关性容积损失
潜在的迹象
Region
Feasibility Development Confirmation Status
Status
寺庙增大
US
US approved
approved
Tropoelastin
Facial Aesthetics Device Skin Deformities Aesthetics
潜在的迹象
Region
Feasibility Development Confirmation Status
Status
Atrophic Scars
N A
N A confirmation
confirmation
HArmonyCa™
Facial Aesthetics Device Facial Contouring Aesthetics Combination
潜在的迹象
Region
Feasibility Development Confirmation Status
Status
Facial Volume
EU N A
EU approved
N A development
approved
development
Juvederm®volbella®xc
Facial Aesthetics Device Aesthetics Combination 眼眶下的挖空
潜在的迹象
Region
Feasibility Development Confirmation Status
Status
眼眶下的挖空
US
US approved
approved
Resonic
Body Contouring Device Cellulite Aesthetics
潜在的迹象
Region
Feasibility Development Confirmation Status
Status
Cellulite
N A
N A development
development
Juvederm®volite®xc
Facial Aesthetics Device Skin Deformities Aesthetics Combination
潜在的迹象
Region
Feasibility Development Confirmation Status
Status
细线还原
US , EU , JA
US , EU , JA approved
approved
颈线缩小
N A
N A confirmation
confirmation
Juvederm®volux®xc
Facial Aesthetics Device Jawline Definition Aesthetics Combination
潜在的迹象
Region
Feasibility Development Confirmation Status
Status
Jawline Definition
US
US approved
approved
新一代胶原蛋白填充剂
Facial Aesthetics Device Facial Contouring Aesthetics
潜在的迹象
Region
Feasibility Development Confirmation Status
Status
Facial Volume
N A
N A confirmation
confirmation
No Results Found 更改过滤或搜索条件.
Popular pages
External links

除非另有规定, 本网站出现的所有产品名称均为M8体育官网所有或授权的商标.、其子公司或附属公司. 不得使用任何m8体育商标, trade name, 在未经M8体育官网事先书面授权的情况下，可以在本网站内使用或使用商业外观.除外，以识别本公司的产品或服务.

版权所有©2024M8体育官网. 北芝加哥，伊利诺伊州，美国.S.A.